Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 11.30 NOK
Change Today +0.50 / 4.63%
Volume 6.3K
NAVA On Other Exchanges
As of 10:25 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

navamedic (NAVA) Snapshot

10.80 NOK
Previous Close
10.80 NOK
Day High
11.30 NOK
Day Low
10.80 NOK
52 Week High
09/18/14 - 13.50 NOK
52 Week Low
03/31/15 - 9.80 NOK
Market Cap
Average Volume 10 Days
0.35 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for NAVAMEDIC (NAVA)

Related News

No related news articles were found.

navamedic (NAVA) Related Businessweek News

No Related Businessweek News Found

navamedic (NAVA) Details

Navamedic ASA, a pharmaceutical company, in-licenses, buys, and markets pharmaceuticals and other health care products in northern Europe. Its product portfolio includes original and generic pharmaceuticals, as well as food supplements, medical devices, and other health care products. The company also distributes medical nutrition products for various metabolic disorders, including phenylketonuria, tyrosinemia, maple sirup urine disease, homocystinuria, methylmalonic acidemia, propionic acidemia, and glutaric aciduria type 1, as well as carbohydrate metabolism, fat metabolism, and renal diseases. In addition, it sells consumer care products consisting non-prescription drugs and health care products primarily through pharmacies and/or drugstores. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Lysaker, Norway.

Founded in 2002

navamedic (NAVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

navamedic (NAVA) Key Developments

Navamedic ASA Reports Earnings Results for the Second Quarter and Six Months of 2015

Navamedic ASA reported earnings results for the second quarter and six months of 2015. For the quarter, the company reported sales of NOK 59.6 million compared to NOK 59.5 million a year ago. The company's EBITDA for the quarter was NOK 3.5 million compared to NOK 3.0 million the second quarter of 2014. Earnings before taxes for the second quarter this year ended at NOK 1.0 million, against NOK 0.2 million last year. For the six months, the company reported sales ended at NOK 121.5 million against NOK 102.4 million last year, a sales growth of 19%. EBITDA for the first half was NOK 7.7 million, up from NOK 5.0 million last year. Earnings before taxes for the first half came in at NOK 2.5 million, compared to NOK 0.5 million in 2014.

Navamedic ASA Launches New Pharmaceutical Product

Navamedic ASA announced that the company is launching a new pharmaceutical product, aimed at reducing acid production in the stomach. Initially, the generic drug Esomeprazole Navamedic will be launched in Finland, which offers the Nordic region's best market conditions for generic drugs. The total Finnish market for this particular product and its competitors is approximately NOK 30 million. Esomeprazole Navamedic will also be introduced in the Swedish market, while the other Nordic markets offer limited potential for this particular product.

Navamedic ASA Announces Financial Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for 2015

Navamedic ASA announced financial results for the first quarter ended March 31, 2015. The company's profitability improved significantly from last year's first quarter, while sales increased by 44%. Sales were NOK 61.8 million in the first quarter, compared to NOK 42.9 million last year. The company's EBITDA for the quarter was NOK 4.2 million, compared to NOK 2.0 million the first quarter of 2014. Earnings before taxes for the first quarter was NOK 1.5 million, against NOK 0.2 million last year. EBIT was NOK 1.8 million compared to NOK 19,000 a year ago. Net cash from operations was NOK 1.8 million compared to net cash used in operations of NOK 0.2 million last year. Net profit was NOK 1.3 million or NOK 0.15 per diluted share, compared to NOK 13,000 in the first quarter of 2014. Purchase of intangible assets was NOK 672,000 compared to NOK 204,000 in the first quarter of 2014. The company's strategy is to improve profitability through increased sales of its existing and new products, and will represent top line growth in 2015. Margins will improve, however, and the Board expects continued growth in EBITDA. In 2015, the company will continue to focus on strengthening its product portfolio and will prioritize efforts in the Nordic region. In the Nordics the company's product margins are higher and sales and marketing capabilities are strong.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVA:NO 11.30 NOK +0.50

NAVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NAVA.
View Industry Companies

Industry Analysis


Industry Average

Valuation NAVA Industry Range
Price/Earnings 29.5x
Price/Sales 0.4x
Price/Book 0.8x
Price/Cash Flow 7.0x
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVAMEDIC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at